For example, in lung adenocarcinoma, EGFR testing for mutations and ALK rearrangements allows for precision therapy with targeted kinase inhibitors, such as gefitinib for EGFR and Crizotinib for ALK fusion [137]. This evidence concerns the gene EGFR and lung adenocarcinoma.